Kaken Pharmaceutical (4521) · RiskFirst stated

Risks related to investment, regulation and political and economic conditions accompanying overseas expansion

First written in FY2026. . Latest entry: FY2026.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Risks associated with overseas store expansion, including legal and cultural adaptation, foreign exchange, and investment recoveryA theme 6 companies write about · 6 as a headwind · 0 as a tailwind

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Full recordFilings, disclosures and news, newest first

FY2026First statedAnnual report
「Overseas expansion requires substantial ongoing investment. If the Group is unable to completely avoid risks such as changes in regulations and systems in each country, shifts in political and economic conditions, and deterioration in diplomatic relations, these risks may have a material impact on the Group’s operating results and financial condition.」
With the expansion of overseas operations, including the establishment of an in-house sales platform in the US market, ongoing investment requirements, regulations and systems in each country, political and economic conditions, and changes in diplomatic relations were disclosed independently as major risks for the first time.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

Kaken Pharmaceutical's next results are scheduled for 2026-11-09. Read the earnings preview

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.